App-Quantinova.ai

OUTCOMES OF VASCULAR INTERVENTIONS IN TAKAYAS-S ARTERITIS; A RETROSPECTIVE COHORT STUDY

C. H. Labarca - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

ENDOTHELIAL PROGENITOR CELLS IN TAKAYAS-S ARTERITIS

E. D. Ersozlu Bozkirli - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

A RARE BUT LIFE-THREATENING PRESENTATION OF BEHCET'S DISEASE: INTRA-CARDIAC THROMBUS

H. Emmungil - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Cyclophosphamide

MORTALITY OF OF SYSTEMIC VASCULITIS IN RHEUMATOID ARTHRITIS AND IN PROGRESSIVE SYSTEMIC SCLEROSIS A COMPARATIVE POSTMORTEM STUDY OF 36 RA AND 11 SSC PATIENTS

A. Apathy - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Venous thrombosis

N/A

BEHCE-S DISEASE IN MOROCCO: REPORT OF 1484 CASES

F. Z. Alaoui - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methadone hydrochloride

COMPARISON OF HISTOPATHOLOGICAL FINDINGS WITH CLINICAL MANIFESTATIONS IN A LARGE SINGLE CENTER COHORT OF PATIENTS WITH BIOPSY-PROVEN GIANT CELL ARTERITIS

F. Muratore - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

TAKAYAS-S ARTERITIS AND FACTORS AFFECTING THE COURSE AND PROGNOSIS

E. N. Scryabina - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

N/A

CLINICAL AND EPIDEMIOLOGICAL FEATURES AND MANAGEMENT OF BEHCET DISEASE IN A BRAZILIAN TERTIARY HOSPITAL

M. Lima Gomes Ochtrop - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Methylprednisolone

ANTI-TNF TREATMENT FOR REFRACTORY VASCULAR INVOLVEMENT OF BEHCET'S SYNDROME: A REPORT OF 16 PATIENTS

V. Hamuryudan - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Cyclophosphamide

SYSTEMIC LUPUS ERYTHEMATOSUS AND THE ANTIPHOSPHOLIPID SYNDROME

R. Derksen - European League Against Rheumatism (EULAR) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Hydroxychloroquine

SURVIVAL IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION IN THE MODERN TREATMENT ERA: RESULTS FROM A MULTICENTRE AUSTRALIAN COHORT STUDY

K. Morrisroe - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Venous thrombosis

Hydroxychloroquine

THE CUMULATIVE NUMBER OF MICRO-HAEMORRHAGES AND MICRO-THROMBOSIS IN NAILFOLD VIDEOCAPILLAROSCOPY IS A GOOD PREDICTOR OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS: A VALIDATION STUDY OF NEMO SCORE

N. Del Papa - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

N/A

HIGHER FIBRINOGEN PLASMA LEVELS AT BASELINE ARE ASSOCIATED WITH A FASTER DEVELOPMENT OF NEW DIGITAL PITTING SCARS/ULCERS AT FOLLOW-UP IN SYSTEMIC SCLEROSIS PATIENTS

S. Vettori - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Venous thrombosis

Fibrinogen (IV)

RISK FACTORS FOR THROMBOEMBOLIC EVENTS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES

A. Notarnicola - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

Methadone hydrochloride

THE CLINICAL SIGNIFICANCE OF ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC SCLEROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Merashli - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Venous thrombosis

N/A

OUTCOME OF PREGNANCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, PREVALENCE OF MATERNAL, OBSTETRIC, AND FETAL COMPLICATIONS

H. Alkoky - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

RECURRENT THROMBOSIS IN YOUNG PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE RELEVANCE OF THE ANTIPHOSPHOLIPID ANTIBODY PROFILE

M. Rodrigues - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Hydroxychloroquine

PRESENCE OF IMMUNOGLOBULIN (IG) A ANTIBODIES AGAINST CARDIOLIPIN AND ?2-GLYCOPROTEIN-I IN THE ABSENCE OF IGG AND IGM IN SYSTEMIC LUPUS ERYTHEMATOSUS

M. Frodlund - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

N/A

THROMBOCYTOPENIA IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A PARADOXICAL THROMBOTIC RISK FACTOR

R. Hisada - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Phosphatidylserine

COMPARISON BETWEEN JUVENILE-, ADULT-, AND LATE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS

S.V. Monov - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Venous thrombosis

Glucocorticoid

Filters

7277 Abstracts